Defensive Giants PG, JNJ, and KO Poised for 2027 Growth Spurt

Three defensive blue chip stocks stand out as durable compounders heading into 2027: Procter & Gamble (NYSE:PG), Johnson & Johnson (NYSE:JNJ), and Coca-Cola (NYSE:KO). Consumer sentiment is at recessionary levels, but staples and healthcare names are gaining relevance. With PG trading near 22x earnings, JNJ's oncology pipeline driving growth, and KO's World Cup campaign as a catalyst, these stocks could surprise investors next year.

PG needs to reach $180 in 2027, with CEO Shailesh Jejurikar promising productivity gains that will offset commodity headwinds. The company has increased its dividend for 70 consecutive years, and its FY2026 revenue grew 3.26% to $87.03B.

JNJ needs a 17% price increase to hit $300 in 2027, with management raising FY2026 guidance to $100.3-$101.3B revenue and adjusted EPS of $11.45-$11.65. Oncology is the engine driving growth, with DARZALEX, TREMFYA, and RYBREVANT/LAZCLUZE all showing strong results.

KO is trading at a P/E of 26, and reaching $100 in 2027 would push that to 29x, a premium justified by its growth profile. The company has raised guidance for organic revenue growth of 5% and comparable EPS growth of 9%-10%, with new CEO Henrique Braun citing the FIFA World Cup campaign as a key demand catalyst.